Overview

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Status:
NOT_YET_RECRUITING
Trial end date:
2031-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Phase:
PHASE3
Details
Lead Sponsor:
GlaxoSmithKline